WO2003027145A1 - Inducteur de mort cellulaire, cellules et animaux exprimant cet inducteur, et procede de criblage de medicament anti-mort cellulaire - Google Patents

Inducteur de mort cellulaire, cellules et animaux exprimant cet inducteur, et procede de criblage de medicament anti-mort cellulaire Download PDF

Info

Publication number
WO2003027145A1
WO2003027145A1 PCT/JP2002/009959 JP0209959W WO03027145A1 WO 2003027145 A1 WO2003027145 A1 WO 2003027145A1 JP 0209959 W JP0209959 W JP 0209959W WO 03027145 A1 WO03027145 A1 WO 03027145A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell death
remedy
screening
diseases caused
cells
Prior art date
Application number
PCT/JP2002/009959
Other languages
English (en)
Japanese (ja)
Inventor
Ryosuke Takahashi
Yasuyuki Suzuki
Yuzuru Imai
Koji Takio
Hiroshi Nakayana
Original Assignee
Riken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riken filed Critical Riken
Publication of WO2003027145A1 publication Critical patent/WO2003027145A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne une nouvelle protéine participant à la mort cellulaire et un gène codant pour cette protéine; l'utilisation de la protéine ou du gène précité afin de cribler un facteur anti-mort cellulaire destiné à traiter des maladies induites par la mort cellulaire excessive ou un médicament destiné à traiter des maladies induites par l'inhibition anormale de la mort cellulaire; et des procédés de criblage. L'invention concerne également HtrA2 humain et des cellules et des animaux exprimant HtrA2 humain permettant de cribler un facteur anti-mort cellulaire destiné à traiter des maladies induites par la mort cellulaire excessive; un procédé de criblage de facteur anti-mort cellulaire destiné à traiter des maladies induites par la mort cellulaire excessive; et un procédé de criblage de médicament permettant de traiter des maladies induites par une inhibition anormale de la mort cellulaire.
PCT/JP2002/009959 2001-09-26 2002-09-26 Inducteur de mort cellulaire, cellules et animaux exprimant cet inducteur, et procede de criblage de medicament anti-mort cellulaire WO2003027145A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-294794 2001-09-26
JP2001294794 2001-09-26

Publications (1)

Publication Number Publication Date
WO2003027145A1 true WO2003027145A1 (fr) 2003-04-03

Family

ID=19116336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/009959 WO2003027145A1 (fr) 2001-09-26 2002-09-26 Inducteur de mort cellulaire, cellules et animaux exprimant cet inducteur, et procede de criblage de medicament anti-mort cellulaire

Country Status (1)

Country Link
WO (1) WO2003027145A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030256A1 (fr) * 2003-09-30 2005-04-07 Daiichi Pharmaceutical Co., Ltd. Inhibition de la mort des cellules nerveuses par inhibition de la degradation de shc3, atf6 ou crebl1 par htra2 et procede d'amelioration des maladies neurodegeneratives
CN113265387A (zh) * 2021-01-22 2021-08-17 中国人民解放军军事科学院军事医学研究院 一种成熟HtrA2突变体N196C及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828003A2 (fr) * 1996-09-06 1998-03-11 Smithkline Beecham Plc Sérine protéase humaine
WO1998050406A1 (fr) * 1997-05-09 1998-11-12 The General Hospital Corporation Genes associes a la proliferation cellulaire
WO1999036550A2 (fr) * 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Molecules de proteases humaines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828003A2 (fr) * 1996-09-06 1998-03-11 Smithkline Beecham Plc Sérine protéase humaine
WO1998050406A1 (fr) * 1997-05-09 1998-11-12 The General Hospital Corporation Genes associes a la proliferation cellulaire
WO1999036550A2 (fr) * 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Molecules de proteases humaines

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
FACCIO L. ET AL.: "Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia", J. BIOL. CHEM., vol. 275, no. 4, 2000, pages 2581 - 2588, XP002957684 *
GRAY C.W. ET AL.: "Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response", EUR. J. BIOCHEM., vol. 267, no. 18, 2000, pages 5699 - 5710, XP002957685 *
HEDGE R. ET AL.: "Identification of Omi/HtrA2 as a mitochondria 1 apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction", J. BIOL. CHEM., vol. 277, no. 1, January 2002 (2002-01-01), pages 432 - 438, XP002957690 *
HU S.I. ET AL.: "Human HtrA, an evolutionary conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage", J. BIOL. CHEM., vol. 273, no. 51, 1998, pages 34406 - 34412, XP002930913 *
MARTINS L.M. ET AL.: "The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif", J. BIOL. CHEM., vol. 277, no. 1, January 2002 (2002-01-01), pages 439 - 444, XP002957688 *
SAVOPOULOS J.W. ET AL.: "Expression purification and functional analysis of the human serine protease HtrA2", PROTEIN EXPR. PURIF., vol. 19, no. 2, 2000, pages 227 - 234, XP002957686 *
SUZUKI Y. ET AL.: "A serine protease, HtrA2, is related from the mitochondria and interacts with XIAP, inducing cell death", MOL. CELL, vol. 8, no. 3, 28 September 2001 (2001-09-28), pages 613 - 621, XP002957687 *
VAN LOO G. ET AL.: "The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity", CELL DEATH DIFFER, vol. 9, no. 1, January 2002 (2002-01-01), pages 20 - 26, XP002957691 *
VERHAGEN A.M. ET AL.: "HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins", J. BIOL. CHEM., vol. 277, no. 1, January 2002 (2002-01-01), pages 445 - 454, XP002957689 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030256A1 (fr) * 2003-09-30 2005-04-07 Daiichi Pharmaceutical Co., Ltd. Inhibition de la mort des cellules nerveuses par inhibition de la degradation de shc3, atf6 ou crebl1 par htra2 et procede d'amelioration des maladies neurodegeneratives
CN113265387A (zh) * 2021-01-22 2021-08-17 中国人民解放军军事科学院军事医学研究院 一种成熟HtrA2突变体N196C及其制备方法和应用
CN113265387B (zh) * 2021-01-22 2022-05-20 中国人民解放军军事科学院军事医学研究院 一种成熟HtrA2突变体N196C及其制备方法和应用

Similar Documents

Publication Publication Date Title
WO2006092668A3 (fr) Compositions proteiques de cellules cutanees foetales pour le traitement d'affections, de troubles ou de maladies cutanes et procedes de fabrication et d'utilisation de celles-ci
DE60239669D1 (de) Sojabohnenprotein, verfahren zu seiner herstellung sowie dessen säure enthaltende proteinnahrungsmittel
WO2008063382A3 (fr) Antagonistes de pcsk9
WO2008057457A3 (fr) Antagonistes de pcsk9
WO2008133647A3 (fr) Antagonistes de pcsk9
WO2003089619A3 (fr) Cellules souches placentaires et utilisations
AU2003270626A1 (en) Magnetically modified electrodes as well as methods of making and using the same
WO2002015920A3 (fr) Traitement des maladies d'hyperproliferation
WO2005016947A3 (fr) Modulation antisens de l'expression de la kinase proteine activee par le mitogene p38
AU2003249645A1 (en) METHODS FOR THE IDENTIFICATION OF IKKAlpha FUNCTION AND OTHER GENES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES
SI1575951T1 (sl) Heterociklične spojine, postopki za njihovo izdelavo in njihova uporaba v terapiji
WO2003097810A3 (fr) Nitrilases, acides nucleiques les codant et leurs procedes de production et d'utilisation
WO2003002108A3 (fr) Utilisation d'inhibiteurs de tyrosine kinase destines au traitement de maladies inflammatoires
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
WO2004032850A3 (fr) Utilisations d'antagonistes des zven humaines
AU2001251507A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2003027145A1 (fr) Inducteur de mort cellulaire, cellules et animaux exprimant cet inducteur, et procede de criblage de medicament anti-mort cellulaire
WO2001054707A3 (fr) Utilisation d'au moins un inhibiteur d'aminopeptidase
ITRM20030589A1 (it) Metodo esperto di ricerca, redazione ed edizione di
WO2000064422A3 (fr) Nouveau traitement
ATE382620T1 (de) Pyrano, piperidino, und thiopyrano derivate und methode zur verwendung
WO2002062205A3 (fr) Methodes de diagnostic et de traitement des cardiopathies
AU2001256998A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
AU2001251508A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2003032899A3 (fr) Procedes et materiaux permettant de cibler et d'affecter des cellules selectionnees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP